Search
Valanafusp alfa
go.drugbank.com/drugs/DB15336InvestigationalValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
JNJ-27548547
go.drugbank.com/drugs/DB15372InvestigationalJNJ-27548547 is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).
BMS-754807
go.drugbank.com/drugs/DB15399InvestigationalBMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).
Technetium Tc-99m epratuzumab
go.drugbank.com/drugs/DB15452ExperimentalTechnetium Tc-99m epratuzumab is under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma).
Diflomotecan
go.drugbank.com/drugs/DB16138InvestigationalDiflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).
Eltanexor
go.drugbank.com/drugs/DB16153InvestigationalEltanexor is under investigation in clinical trial NCT02649790 (Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/refractory Cancer Indications).
Tiropramide
go.drugbank.com/drugs/DB13091InvestigationalTiropramide is under investigation in clinical trial NCT01629212 (Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome).
WGc-0201
go.drugbank.com/drugs/DB22819InvestigationalWGc-0201 is under investigation in clinical trial NCT07077369 (WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy).
Plazinemdor
go.drugbank.com/drugs/DB21493InvestigationalPlazinemdor is a small molecule drug. Plazinemdor is under investigation in clinical trial NCT04306146 (Study of CAD-9303 in Subjects With Schizophrenia).
Ulixertinib
go.drugbank.com/drugs/DB13930InvestigationalIt is currently in clinical trials for the treatment of a wide range of tumors. … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity [A31474].